Posts
- Category: General
- Category: Health and Wellness
- Category: Medicine
- Category: News
- American Stock Exchange Accepts Callisto Pharamceuticals’ Plan of Compliance and Extension to Regain Compliance with Standards
- Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis Announces Positive Data in Animal Models of Ulcerative Colitis
- Callisto Pharmaceuticals Announces Appointment of Chairman of Scientific Advisory Board
- Callisto Pharmaceuticals Announces Article Citing Atiprimod in Major Scientific News Journal
- Callisto Pharmaceuticals Announces Dr. Moshe Talpaz to Join Scientific Advisory Board
- CALLISTO PHARMACEUTICALS ANNOUNCES FILING OF IND ON ATIPRIMOD FOR MULTIPLE MYELOMA
- Callisto Pharmaceuticals Announces Patient Dosing in L-Annamycin Phase I Clinical Trial in Pediatric Relapsed or Refractory Acute Leukemia
- Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma Article Published in Recent Issue of Journal Blood
- Callisto Pharmaceuticals CEO Releases Letter to Shareholders Describing Recent Accomplishments
- Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
- Callisto Pharmaceuticals Files Suit Against Former Executive Vice President for Breach of Employment Agreement, Fraud, Conversion and Related Claims
- CALLISTO PHARMACEUTICALS GRANTED ORPHAN DRUG DESIGNATION FOR ATIPRIMOD FOR MULTIPLE MYELOMA INDICATION
- Callisto Pharmaceuticals Opens Additional Site for Phase II Clinical Trial of Atiprimod in Carcinoid Cancer Patients
- Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
- Callisto Pharmaceuticals Opens Fourth Site for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
- Callisto Pharmaceuticals Opens L-Annamycin Phase I Clinical Trial in Pediatric Relapsed or Refractory Acute Leukemia
- Callisto Pharmaceuticals Opens Second Site for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
- Callisto Pharmaceuticals Presents Preclinical Findings on Its Lead Drug Candidate for Multiple Myeloma
- Callisto Pharmaceuticals Raises $11.2 Million in Series B Preferred Stock Financing
- CALLISTO PHARMACEUTICALS RECEIVES STTR/NIH GRANT AWARD
- Callisto Pharmaceuticals to Present at BIO CEO & Investor Conference Wednesday 14 February 2007
- Callisto Pharmaceuticals to Present at Rodman & Renshaw Techvest Healthcare Conference
- Callisto Pharmaceuticals to Present at the Acumen Biofin Rodman & Renshaw 4th Annual Global Healthcare Conferences
- Callisto Pharmaceuticals to Present Poster on Its Lead Drug Candidate for Multiple Myeloma at Conference on Molecular Targets and Cancer Therapeutics
- Callisto Reports on 2006 and First-Quarter 2007 Clinical and Corporate Milestones and Achievements
- Callisto Reports on Second-Quarter 2007 Milestones
- Callisto's Cancer Drug Atiprimod to Be Presented at Scientific Conference on Cancer Drugs and Angiogenesis
- Callisto's Cancer Drug Atiprimod to Be Presented at the Annual Meeting of American Association of Cancer Research
- First Berlin Releases Research Update Following Callisto Pharmaceutical's 2006 Fiscal Year Results and Pipeline update
- First Berlin Releases Research Update Following Callisto Pharmaceutical's Announcement of $5.75 Million Preferred Stock Financing
- Publication of Early Research on Callisto Pharmaceutical's Degrasyn Drug Class Suggests Potential to Treat Brain Tumors
- RESEARCH PRESENTED ON CALLISTO PHARMACEUTICALS’ LEAD DRUG CANDIDATE FOR MULTIPLE MYELOMA
- Rodman and Renshaw Releases Research Report on Callisto Pharmaceuticals, Inc. Initiates Coverage with Market Outperform Rating and a price target of $3.00 per share
- Category: Unspecified
Pages
- About
- Albert J. Henry, M.B.A.
- ANNUAL MEETING OF STOCKHOLDERS
- Archived News
- Bernard F. Denoyer, CPA
- Biodefence Program introduction
- Biological studies on Multiple Myeloma
- Callisto R&D Facility
- Callisto Stock Information
- Careers
- Christoph Bruening
- Clinical studies
- Clinical summary
- Clinical Trials
- Collaborators
- Contact
- Diagnostic Test for OCD
- Disclaimer
- Donald H. Picker, Ph.D.
- DRUG PIPELINE GOALS
- Edwin Snape, Ph. D.
- Gabriele M. Cerrone, M.B.A.
- Gary S. Jacob, Ph.D.
- GCRA for Colon Cancer
- GCRA Publications
- GCRA Publications
- GUANLIB
- Iain Ross
- INFORMATION FOR PATIENTS
- Investor Relations
- Kunwar Shailubhai, Ph.D. & M.B.A.
- Legal
- Michael Zelefsky, M.D.
- News
- News
- Open Positions
- Personnel and staff
- Pipeline
- PROFILE
- SEC Filings
- SHAREHOLDER FAQ
- Sitemap
- Technology Page
- Third Party Entry
- Welcome to callisto pharmaceuticals